Mutations in IDH1 (~80% of grade II-III gliomas and secondary GBMs and ~5% of primary GBMs) and less frequently IDH2 are characteristic of secondary GBM and are associated with a better prognosis [28,33]. This evidence concerns the gene IDH1 and glioma.